Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to octreotide therapy and do not correlate with tumor histology

European Journal of Endocrinology

Volumn 136, Issue 4, 1997, Pages 369-376

  Plökinger, Ursula ^a,c   Bäder, Michael ^a   Hopfenmüller, Werner ^a   Saeger, Wolfgang ^b   Quabbe, Hans Jürgen ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b Marienkrankenhaus   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE; PENTETREOTIDE; PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; INTRAVENOUS DRUG ADMINISTRATION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR VOLUME;

EID: 1842333956     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1360369     Document Type: Article

References (33)

1. Lamberts SWJ, Krenning EP & Reubi J-C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrine Reviews 1991 12 450-482.
2. 3]-octreotide: the Rotterdam experience with more than 1000 patients. European Journal of Nuclear Medicine 1993 20 716-731.
3. 111In-pentetreotide for endocrine gastroenteropancreatic tumors. Hormone and Metabolic Research 1993 Supplement Series 27 28-35.
4. Scherübl H, Bäder M, Fett U, Hamm B, Schmidt-Gayk H, Koppenhagen K et al. Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors. Gastroenterology 1993 105 1705-1709.
5. 123I]SDZ 204-090). Journal of Clinical Endocrinology and Metabolism 1991 73 850-856.
6. Ur E, Mather SJ, Bomanji J, Ellison D, Britton KE, Grossman AB et al. Pituitary imaging using a labelled somatostatin analogue in acromegaly. Clinical Endocrinology 1992 36 147-150.
7. De Bruin TWA, Kwekkeboom DJ, Van't Verlaat JW, Reubi J-C, Krenning EP, Lamberts SWJ et al. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. Journal of Clinical Endocrinology and Metabolism 1992 75 1310-1317.
8. Lamberts SWJ, Hofland LJ, de Herder WW, Kwekkeboom DJ, Reubi J-C & Krenning EP. Octreotide and related somatostatin analogs in the diagnosis and treatment of pituitary disease and somatostatin receptor scintigraphy. Frontiers in Neuroendocrinology 1993 14 27-55.
9. Duet M, Mundler O, Ajzenberg C, Berolatti B, Chedin P, Duranteau L et al. Somatostatin receptor imaging in non-functioning pituitary adenomas: value of an uptake index. European Journal of Nuclear Medicine 1994 21 647-650.
10. Plöckinger U, Reichel M, Fett U, Saeger W & Quabbe H-J. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. Journal of Clinical Endocrinology and Metabolism 1994 79 1416-1423.
11. Daneshdoost L, Gennarelli TA, Bashey HM, Savino PJ, Sergott RC, Bosley TM et al. Recognition of gonadotroph adenomas in women. New England Journal of Medicine 1991 324 589-594.
12. Lundin P & Pedersen F. Volume of pituitary macroadenomas: Assessment by MRI. Journal of Computer Assisted Tomography 1992 16 519-528.
13. Kovacs K & Horvath E. Tumors of the pituitary gland. In Atlas of Tumor Pathology, fascicle 21, 2nd scries pp 1-269. Eds WH Hartmann & LH Sobin. Washington, DC: Armed Forces Institute of Pathology, 1986.
14. Scheidhauer K, Hildebrandt G, Luyken C, Schomäcker K, Klug N & Schicha H. Somatostatin receptor scintigraphy in brain tumors and pituitary tumors: first experiences. Hormone and Metabolic Research 1993 Supplement Series 27 59-62.
15. Bazzoni N, Farabola M, Arosio M, Casati G & Faglia G. Is the effect of octreotide therapy in patients with functionless pituitary adenomas predictable? Journal of Endocrinological Investigation 1991 14 (Suppl 2) 53 (Abstract).
16. Colao A, Ferone D, Lastoria S, Marzullo P, Cerbone G, Di Sarno A et al. Prediction of efficacy of octreotide therapy in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 1996 81 2356-2362.
17. Reubi JC & Landolt AM. The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. Journal of Clinical Endocrinology and Metabolism 1989 68 844-850.
18. Trautmann ME, Neuhaus Ch, Lenze H, Benning R, Benning M, Dennler HJ et al. The role of somatostatin analogs in the treatment of endocrine gastrointestinal tumors. Hormone and Metabolic Research 1993 Supplement Series 27 24-27.
19. Moyse E, Le Dafniet M, Epelbaum J, Pagesy P, Peillon F, Kordon C et al. Somatostatin receptors in human growth hormone and prolactin-secreting pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 1985 61 98-103.
20. Reubi JC, Heitz PU & Landolt AM. Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas: Evidence for different tumor subclasses. Journal of Clinical Endocrinology and Metabolism 1987 65 65-73.
21. de Herder WW, Kwekkeboom DJ, Reijs AEM, Kooy PPM, Holland LJ, Krenning EP et al. Clinical significance of dopamine D2 and somatostatin receptor scintigraphy. (Abstract S28). 4th International Pituitary Congress, San Diego, 16-18 June 1996.
22. Bertherat J, Chanson P, Dewailly D, Dupuy M, Jaquet P, Peillon F et al. Somatostatin receptors, adenylate cyclase activity, and growth hormone (GH) response to octreotide in GH-secreting adenomas. Journal of Clinical Endocrinology and Metabolism 1993 77 1577-1583.
23. Miller GM, Alexander JM, Bikkal HA, Katznelson L, Zervas NT & Klibanski A. Somatostatin receptor subtype gene expression in pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 1995 80 1386-1392.
24. Panetta R & Patel YC. Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sciences 1995 56 333-342.
25. Greenman Y & Melmed S. Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. Journal of Clinical Endocrinology and Metabolism 1994 78 398-403.
26. Reubi JC, Schaer JC, Waser B & Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Research 1994 54 3455-3459.
27. Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. Journal of Clinical Investigation 1994 93 1321-1325.
28. 1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: Synthesis, radiolabeling and in vitro validation. Life Sciences 1991 49 1583-1591.
29. Hofland LJ, van Koetsveld PM, Waaijers M & Lamberts SWJ. Internalization of isotope-coupled somatostatin analogues. Digestion 1996 57 Suppl 1 2-6.
30. Dörr U, Wurm K, Höring E, Guzman G, Räth U & Bihl H. Diagnostic reliability of somatostatin receptor scintigraphy during continuous treatment with different somatostatin analogs. Hormone and Metabolic Research 1993 Supplement Series 27 36-43.
31. 111In-octreotide scintigraphy. Clinical Endocrinology 1993 39 239-243.
32. Ørskov H. Commentary. Clinical Endocrinology 1993 39 244.
33. Saeger W, Günzl H, Meyer M, Schulze C & Lüdecke DK. Immunohistological studies on clinically silent pituitary adenomas. Endocrine Pathology 1990 1 37-44.